World Sleep Industry ENCYCLOPEDIA

Traditional Herbal Medicinal Products

2.1.2

Definition and category boundary

A traditional herbal medicinal product is a finished product whose active components consist of one or more herbal substances or herbal preparations and that is supplied under a traditional-use, well-established-use, or full medicinal-product pathway in a particular jurisdiction. It belongs to WSIC 2.1.2. A herbal substance may be a whole plant or a specified root, rhizome, leaf, flower, fruit, seed, bark, or other part. Herbal preparations include cut or powdered material, expressed juice, tinctures, essential oils, and materials produced by extraction, concentration, or fermentation. The category name describes source and formulation; it does not mean that every product is authorized as a sleep aid.

Traditional herbal medicines can sit near traditional Chinese medicine formulas, single-ingredient botanical extracts, herbal teas, foods, dietary supplements, aromatic products, and highly purified chemicals isolated from plants. Plant origin alone does not make those categories interchangeable. Oral, topical, inhaled, and bath routes also cannot be substituted for one another. This entry addresses the general product class. Sleep-aid products registered in individual countries form a narrower jurisdiction-specific class, and their actual legal identity depends on the authorization, label, and leaflet recognized by the authority where they are sold.

Regulatory pathways and traditional evidence

Jurisdictions classify botanical products differently and impose different requirements for indications and premarket evidence. The European Union traditional-use route, for example, requires a sufficiently long medicinal-use history, acceptable safety, plausible action, and use at a specified dose for minor conditions that do not require medical supervision. Long use may replace some clinical-trial requirements in that pathway, but it does not mean that efficacy has been demonstrated by the same evidence required for a full new-medicine authorization. Well-established-use authorizations and full applications have different evidentiary thresholds.

A registration number therefore has to be read together with the authorization type, approved indication, dosage form, route, intended age group, and warnings. “Traditional use,” pharmacopoeial inclusion, an official monograph, pharmacy sale, or lawful marketing in one place does not alone establish legality elsewhere. Nor does it expand a limited indication into treatment of chronic insomnia, sleep apnea, or a psychiatric disorder. For cross-border products, the status in the country of origin, classification at the destination, and permitted advertising claims must be checked separately.

Botanical identity and preparation equivalence

The label and technical record should identify every active plant at a useful level: botanical name with author, medicinal part, fresh or dried state, and amount per dose, with subspecies, variety, or chemotype where relevant. One common name can refer to several species, and the root and leaf of the same species can differ in composition and risk. A combination should list each constituent and its amount. Descriptions such as “ancient formula,” “sleep blend,” or a single total weight should not conceal the identity of the individual components.

An extract also needs a preparation type, extraction solvent and concentration, and the ratio of starting herbal substance to the genuine preparation, commonly expressed as a drug-extract ratio. The genuine extract must be distinguished from excipients added for manufacturing. Standardised preparations, quantified preparations, and preparations controlled by analytical markers are not the same concepts. A marker can help confirm identity or consistency without being the sole therapeutically active constituent. Products made from the same species are not equivalent by raw-plant grams or capsule count when their plant part, solvent, ratio, purification, marker range, dosage form, or dose differs.

Manufacture, quality, and batch consistency

Quality control begins with cultivation or collection and should document origin, authentication, harvest period, primary processing, drying, transport, and storage. These controls reduce species substitution, adulteration, mould growth, and compositional drift. Release and shelf-life specifications should address applicable macroscopic or microscopic identity, chromatographic fingerprints, assays or markers, water content, foreign matter, microorganisms, mycotoxins, pesticide residues, heavy metals, residual solvents, and other known hazards. The finished dosage form also needs suitable checks for dose uniformity, disintegration or dissolution, package protection, and storage stability.

A complex combination or highly processed extract may not be fully authenticated by one chemical peak. A certificate, origin story, smell, colour, or “all natural” claim likewise cannot replace validated controls at several levels. Batch consistency means more than similar marker values; it includes the raw-material profile, manufacturing process, finished-product performance, and continued correspondence with the preparation described by the traditional or clinical evidence. A change in species source, extraction solvent, ratio, supplier, or critical process calls for a comparability assessment rather than automatic reuse of earlier evidence.

Sleep evidence and interpretation of outcomes

Sleep evidence must be tied to a defined finished product or adequately comparable preparation, dose, treatment period, population, and indication. Findings for one ethanolic valerian-root extract, one fixed combination, or one traditional preparation do not automatically apply to a tea bearing the same plant name, an extract made with another solvent, an arbitrary blend, or the whole class of herbal medicines. Traditional use may support plausibility under stated conditions, but it cannot be rewritten as “clinically proven,” “fast acting,” or effective for every form of insomnia.

Studies should distinguish sleep-onset latency, awakenings, total sleep time, perceived sleep quality, next-day function, and objective sleep measures, while reporting baseline severity, adverse events, attrition, and concurrent care. Short-term relaxation, drowsiness, or a score change does not establish correction of sleep architecture or durable benefit. Current sleep-medicine guidance supports multicomponent cognitive behavioral therapy for chronic insomnia. A herbal product does not replace evaluation of causes, and a single small study that finds no significant difference does not demonstrate equivalence to established care.

Safe use, interactions, and special populations

Users should follow the authorized leaflet for the single dose, daily frequency, timing, maximum self-care period, missed-dose instructions, and storage. They should not increase the dose, extend treatment, or stack several “natural sleep” products on their own. Herbal preparations can cause drowsiness, gastrointestinal symptoms, headache, allergy, or paradoxical excitation, with the actual risks depending on the formula. Alcohol, prescription hypnotics or sedatives, sedating antihistamines, and other centrally acting products may increase impairment. Other medicines can interact through absorption, metabolism, transport, or coagulation pathways.

Before starting a product, a complete list of prescription medicines, nonprescription medicines, and supplements should be shared with a physician or pharmacist. Plant origin does not establish suitability for children, pregnancy or breastfeeding, older adults, people with hepatic or renal impairment, people with epilepsy, or patients approaching surgery; decisions must follow the specific product information and professional assessment. A first dose and any regimen that causes drowsiness require attention to next-day driving, machinery, work at height, and responsibility for others. Severe allergy, jaundice, altered consciousness, or another marked reaction calls for immediate discontinuation and medical help, with the package and batch number retained for reporting.

Selection, follow-up, and claim boundaries

Selection should rely on a verifiable regulatory record, full composition, manufacturer, batch, expiry, authorized indication, and leaflet rather than ratings, historical stories, or the words “laboratory tested.” During use, the dose time, sleep diary, next-day function, and adverse effects can be recorded. Failure to improve by the review point in the leaflet, worsening symptoms, or a need for continued reliance should end unsupervised trial-and-error and prompt assessment. Suspected quality defects and adverse reactions should be reported through the local pharmacovigilance route, identifying the exact brand, dosage form, and batch.

Persistent insomnia with substantial daytime impairment, loud snoring or witnessed pauses in breathing, unusual sleep behaviors, distressing leg sensations, mania, or severe depression requires targeted evaluation. A traditional herbal medicinal product should not claim to cure insomnia, replace sleep-apnea treatment, remodel sleep stages, have no interactions, suit every age, or be absolutely safe because it is natural. Conformity with quality specifications does not itself prove a sleep benefit. Traditional history, regulatory status, pharmaceutical quality, clinical evidence, and suitability for an individual are separate questions.